Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

• Published in: Life (Basel, Switzerland) Vol. 14; no. 4; p. 524
• Main Authors: Mandala, Evdokia, Lafara, Kyranna, Kokkinovasilis, Dimitrios, Kalafatis, Ioannis, Koukoulitsa, Vasiliki, Katodritou, Eirini, Lafaras, Christos
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2024
• Subjects: Antibodies; Antimitotic agents; Antineoplastic agents; Asymptomatic; Biomarkers; Bispecific antibodies; Blood cancer; Cancer; Cancer therapies; Cardiac arrhythmia; Cardiac function; cardio-oncology; Cardiomyocytes; Cardiotoxicity; Cardiovascular diseases; Care and treatment; Chemotherapy; Chimeric antigen receptors; Collaboration; Complications and side effects; Heart failure; hematological malignancies; Hematology; Hematopoietic stem cells; Hypertension; Immunosuppressive agents; Immunotherapy; Kinases; Leukemia; Lymphocytes; Lymphoma; Lymphomas; Malignancy; Metabolism; multimodality imaging; Multiple myeloma; myocardial dysfunction; Narratives; Oncology; Patients; Peptides; Radiation therapy; Risk factors; Stem cell transplantation; Stem cells; Surveillance; Therapeutic applications; Toxicity; Greece; hematological malignancies; myocardial dysfunction; cardiotoxicity; multimodality imaging; cardio-oncology
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life14040524

Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related cardiotoxicity's definition, risk stratification, multimodality imaging, and use of cardiac biomarkers to detect clinical and/or subclinical myocardial dysfunction and electrical instability. Moreover, the most common cardiotoxic profiles of the main drugs and/or therapeutic interventions in patients with hematological malignancies are described thoroughly.